Transave Signs Cooperative R&D Agreement With NIH

Transave has entered into a co-operative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study ARIKACE in patients with nontuberculous mycobacteria (NTM) lung infections.

Transave and NIAID will collaborate on the planning, design and implementation of a clinical trial to evaluate ARIKACE in patients with NTM lung disease, who have failed to respond to standard, guideline-based treatment regimens.

Reportedly, the study will assess the safety and tolerability of ARIKACE versus placebo administered once daily for several continuous months, using an investigational eFlow Nebulizer System.

Tim Whitten, CEO of Transave, said: This is the third type of chronic lung infection for which ARIKACE is being evaluated. The preliminary success with ARIKACE demonstrating a sustained clinical benefit in treating cystic fibrosis (CF) patients with Pseudomonas lung infections is encouraging as we tackle this additional disease state in collaboration with NIAID.